DLCL.BO · BSE
DR LALCHANDANI LABS LIMITED
₹8.22
+4.85% (+₹0.38)
Prev. close
₹7.84
Volume
4,000
As of
11 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About DR LALCHANDANI LABS LIMITED
Dr Lalchandani Labs Limited provides diagnostic and related healthcare tests and services in India. The company offers doctor consultation, pathology, radiology, hospital lab management, corporate health checkup, and blood bank services, as well as X-ray, TMT, ultrasound, 2D-echo, and medical fitness examinations. It also offers its products online. The company serves individual patients, hospitals and other healthcare providers, and corporate customers. Dr Lalchandani Labs Limited was founded in 1986 and is based in New Delhi, India.
Details
Sector
Healthcare
Industry
Diagnostics & Research
CEO
Mr. Mohit Lalchandani
Headquarters
New Delhi
Website
lalchandanipathlab.comExchange
View on BSE ↗Key stats
Market cap
₹7.10 Cr
P/E ratio (TTM)
117.4
EPS (TTM)
₹0.07
Beta (1Y · daily vs NIFTY 50)
-0.11
Beta (5Y · monthly vs NIFTY 50)
-0.29
Shares float
41.72 L
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (standalone), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.0% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide. EBITDA is omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹9.78 Cr | ₹11.28 Cr | ₹5.04 Cr | ₹4.81 Cr | ₹4.45 Cr | ₹4.19 Cr | |
| EBITDA | — | — | ₹-1.71 L | ₹1.60 Cr | ₹1.05 Cr | ₹68.38 L |
| ₹1.01 Cr | ₹93.30 L | ₹-1.56 Cr | ₹61.75 L | ₹41.72 L | ₹6.35 L | |
| Diluted EPS | — | ₹1.56 | ₹-2.63 | ₹1.04 | ₹0.96 | — |
Depreciation & amortisation, EBITDA, Pretax income, Tax provision, Interest expense, Diluted EPS have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹17.72 Cr | ₹14.99 Cr | ₹15.75 Cr | ₹17.60 Cr | |
| — | — | ₹6.40 Cr | ₹3.48 Cr | ₹4.07 Cr | ₹2.06 Cr | |
| Stockholders' equity | — | — | ₹8.92 Cr | ₹9.54 Cr | ₹9.96 Cr | ₹14.13 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Long-term debt, Current (short-term) debt, Others, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹12,000 | ₹-21.80 L | ₹44.30 L | ₹-76.46 L | |
| Investing cash flow | — | — | ₹-19.66 L | ₹99.65 L | ₹5.87 L | ₹-50.94 L |
| — | — | ₹-23.49 L | ₹-1.59 Cr | ₹50.32 L | ₹2.12 Cr | |
| Capital expenditure | — | — | ₹-30.48 L | ₹-11.50 L | ₹-15.47 L | ₹-33.00 L |
| End cash position | — | — | ₹3.10 Cr | ₹2.29 Cr | ₹3.30 Cr | ₹4.14 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| DR LALCHANDANI LABS LIMITED | ₹7.10 Cr | ₹8.22 | 117.4 | 0.50 | 0.4% | 0.15 | -6.0% | -66.1% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.